Cannabis Use Induces Distinctive Proteomic Alterations in Olfactory Neuroepithelial Cells of Schizophrenia Patients

Barrera-Conde, Marta; Ausín, Karina; Lachén-Montes, Mercedes; Fernández‐Irigoyen, Joaquín; Galindo, L.; Cuenca‐Royo, Aida; Fernández-Avilés, Cristina; Pérez, Ví­ctor; Torre, Rafael de la; Santamaría, Enrique; Robledo, Patricia

doi:10.3390/jpm11030160

Cited by 12 publications

(9 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on this, we selected ZNF326 as a candidate biomarker. Previous studies had indicated that ZNF326 expression was associated with specific disease processes, such as in non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), glioma, and schizophrenia ( 30 - 34 ). Figure S5 shows the distribution in metastatic and non-metastatic patients, tumor and tumor-adjacent tissues.…”

Section: Resultsmentioning

confidence: 99%

ZNF326 as a potential prognostic and predictive biomarker in stage II colorectal cancer

Pu,

Zhang,

Yan

et al. 2024

J Gastrointest Oncol

View full text Add to dashboard Cite

Background Adjuvant chemotherapy is considered for stage II colorectal cancer (CRC) patients with poor prognostic risk factors. However, current stratification algorithms are still insufficient to identify high-risk patients. Methods We conducted a screening strategy to define ZNF326 based on quantitative proteomics in 11 paired CRC patients selected by a nested case-control design, and tested the association between ZNF326 expression level with the prognosis of stage II CRC patients and the benefit from adjuvant chemotherapy in public datasets; further investigation was conducted through subgroup analyses. Results We found that low ZNF326 expression was significantly associated with a lower 5-year overall survival (OS) rate among stage II patients in both the discovery [P=0.008; hazard ratio (HR): 3.13, 95% confidence interval (CI): 1.29–7.58] and validation (P=0.025; HR: 1.98, 95% CI: 1.08–3.65) cohorts. In the Cox multivariable analysis, low ZNF326 expression was both associated with shorter OS after adjustment for age, sex, and adjuvant chemotherapy in the discovery and validation data sets. Subgroup analyses yielded largely similar results. In a pooled database, the rate of 5-year OS was higher among stage II ZNF326 -high tumors who were treated with adjuvant chemotherapy than it was among those who were not treated with adjuvant chemotherapy (P=0.011; HR: 0.28, 95% CI: 0.10–0.80). Conclusions ZNF326 has the potential to be used in clinical practice for risk classification. ZNF326 -low expression level identified a subgroup of patients with high-risk stage II CRC who appeared to less benefit from adjuvant chemotherapy.

show abstract

Section: Resultsmentioning

confidence: 99%

ZNF326 as a potential prognostic and predictive biomarker in stage II colorectal cancer

Pu,

Zhang,

Yan

et al. 2024

J Gastrointest Oncol

View full text Add to dashboard Cite

show abstract

“…A proteomic analysis performed on both neural progenitors and serum from cannabis users described an effect on the “immune system,” specifically proteins related to the interleukin-12 complex and enriched canonical pathways: “activation of liver X receptors/retinoid X receptor” (LXR/RXR), “farnesoid X receptors/retinoid X receptor activation” (FRX/RXR), “acute phase response signaling,” “atherosclerosis signaling and production of NO,” and “ROS in macrophages” ( Alasmari et al, 2021 ; Barrera-Conde et al, 2021 ).…”

Section: Resultsmentioning

confidence: 99%

A Systematic Review of the Molecular and Cellular Alterations Induced by Cannabis That May Serve as Risk Factors for Bipolar Disorder

Delgado-Sequera,

Garcia-Mompo,

Gonzalez-Pinto

et al. 2024

International Journal of Neuropsychopharmacology

View full text Add to dashboard Cite

Background Cannabis use is a risk factor of psychiatric illness, such as bipolar disorder type-I (BDI). Indeed, cannabis use strongly influences the onset and clinical course of BDI, although the biological mechanisms underlying this interaction remain unknown. Therefore, we have reviewed the biological mechanisms affected by cannabis use that may trigger BD. Methods A systematic review was carried out of articles in which gene expression was studied in cannabis users or human-derived cells exposed to THC or CBD. A second systematic review was then performed to identify articles in which gene expression was studied in BDI samples, highlighting those that described alterations to the same molecular and cellular mechanisms affected by cannabis/THC/CBD. Results The initial search identified 82 studies on cannabis and 962 on BDI. After removing duplicates and applying the inclusion/exclusion criteria, 9 studies into cannabis and 228 on BDI were retained. The molecular and cellular mechanisms altered by cannabis use or THC/CBD exposure were then identified, including: neural development and function, cytoskeletal function, cell adhesion, mitochondrial biology, inflammatory related pathways, lipid metabolism, the endocannabinoid system, the hypocretin/orexin system, and apoptosis. Alterations to those activities were also described in 19 of 228 focussed on BDI. Conclusions The biological mechanisms described in this study may be good candidates to the search for diagnostic biomarkers and therapeutic targets for BDI. As cannabis use can trigger the onset of BD, further studies would be of interest to determine whether they are involved in the early development of the disorder, prompting early treatment.

show abstract

“…Amongst these, 102 DEPs were found exclusively in C/c compared to C/nc, and these proteins were predominantly associated with immune system function and RNA metabolism. Overall, their studies have established that cannabis affects the immune system and protein metabolism as the most common deregulated pathways between SCZ patients and cannabis users, as well as pathways pertaining to RNA metabolism, protein localization, and cellular signaling responses to external stimuli [70]. Taken together, these studies highlight the modulatory effects of cannabis on cellular function in the CNS, as well as its impact on the immune system and metabolism.…”

Section: Proteomic Studies On Cannabismentioning

confidence: 94%

A Proteomic View of Cellular and Molecular Effects of Cannabis

Abyadeh¹,

Gupta

Paulo

et al. 2021

Biomolecules

View full text Add to dashboard Cite

Cannabis (Cannabis sativa), popularly known as marijuana, is the most commonly used psychoactive substance and is considered illicit in most countries worldwide. However, a growing body of research has provided evidence of the therapeutic properties of chemical components of cannabis known as cannabinoids against several diseases including Alzheimer’s disease (AD), multiple sclerosis (MS), Parkinson’s disease, schizophrenia and glaucoma; these have prompted changes in medicinal cannabis legislation. The relaxation of legal restrictions and increased socio-cultural acceptance has led to its increase in both medicinal and recreational usage. Several biochemically active components of cannabis have a range of effects on the biological system. There is an urgent need for more research to better understand the molecular and biochemical effects of cannabis at a cellular level, to understand fully its implications as a pharmaceutical drug. Proteomics technology is an efficient tool to rigorously elucidate the mechanistic effects of cannabis on the human body in a cell and tissue-specific manner, drawing conclusions associated with its toxicity as well as therapeutic benefits, safety and efficacy profiles. This review provides a comprehensive overview of both in vitro and in vivo proteomic studies involving the cellular and molecular effects of cannabis and cannabis-derived compounds.

show abstract

Cannabis Use Induces Distinctive Proteomic Alterations in Olfactory Neuroepithelial Cells of Schizophrenia Patients

Cited by 12 publications

References 52 publications

ZNF326 as a potential prognostic and predictive biomarker in stage II colorectal cancer

ZNF326 as a potential prognostic and predictive biomarker in stage II colorectal cancer

A Systematic Review of the Molecular and Cellular Alterations Induced by Cannabis That May Serve as Risk Factors for Bipolar Disorder

A Proteomic View of Cellular and Molecular Effects of Cannabis

Contact Info

Product

Resources

About